focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,774.50
Ask: 1,775.50
Change: 0.00 (0.00%)
Spread: 1.00 (0.056%)
Open: 1,775.50
High: 1,778.50
Low: 1,769.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-GSK-linked investigator freed early from China jail - source

Tue, 09th Jun 2015 14:15

(Adds British consulate statement, GSK no comment, context)

By John Ruwitch

SHANGHAI, June 9 (Reuters) - A British corporateinvestigator linked to a bribery scandal in China involvingdrugmaker GlaxoSmithKline PLC is to be released earlyfrom a 2 1/2-year sentence in a Chinese jail, a source close tohis family said on Tuesday.

Peter Humphrey and his American wife, Yu Yingzeng, weresentenced in August last year for illegally obtaining privaterecords of Chinese citizens and selling the information on toclients including GSK.

The source, who declined to be identified, said Humphrey hadbeen informed on Tuesday by a Shanghai court that his sentencewould be reduced by seven months. He had originally beenexpected to be released in January next year.

The case was intertwined with an investigation of GSK inChina which rocked the country's pharmaceutical market and ledto a $489 million fine against the firm last year for payingbribes to doctors to use its drugs.

Humphrey is in a Shanghai hospital undergoing tests and theBritish consulate is processing an emergency passport for him,so he can be deported once he is released from hospital, thesource said.

It was not clear when Humphrey would officially be released.Yu, who was sentenced to two years in jail, will be freed incoming weeks.

"We have been notified by the Chinese authorities that aBritish national detained in China has been released. We areproviding consular assistance to the family," a spokesman forthe British consulate in Shanghai said.

Humphrey and Yu, who ran risk consultancy ChinaWhys, hadbeen asked by GSK to compile a report into the origins of a sexvideo involving its former China head Mark Reilly, which hadbeen sent to senior executives at the British firm along withanonymous emails alleging corruption.

On July 10, 2013, Chinese authorities detained Humphrey andYu. Days later police accused GSK of funnelling up to 3 billionyuan ($482 million) through travel agencies to bribe doctors andofficials in China.

A UK-based spokesman for GSK declined to comment on thereports that the couple are to be freed. Two lawyers who actedfor Humphrey and Yu last year said they were not aware of thedecision.

President Xi Jinping will travel to Britain for a statevisit in October, 10 years after the last such visit by aChinese president. (Additional reporting by Brenda Goh in Shanghai and BenHirschler in London; Writing by Adam Jourdan; Editing by AndrewRoche)

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.